Long-Term Persisting SARS-CoV-2 RNA and Pathological Findings: Lessons Learnt From a Series of 35 COVID-19 Autopsies.

COVID-19 SARS-CoV-2 RNA PCR autopsy histopathology long-COVID postmortal swabs pulmonary superinfections

Journal

Frontiers in medicine
ISSN: 2296-858X
Titre abrégé: Front Med (Lausanne)
Pays: Switzerland
ID NLM: 101648047

Informations de publication

Date de publication:
2022
Historique:
received: 17 09 2021
accepted: 04 01 2022
entrez: 28 2 2022
pubmed: 1 3 2022
medline: 1 3 2022
Statut: epublish

Résumé

Long-term sequelae of coronavirus disease 2019 (COVID-19), including the interaction between persisting viral-RNA and specific tissue involvement, pose a challenging issue. In this study, we addressed the chronological correlation (after first clinical diagnosis and postmortem) between severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA and organ involvement. The presence of postmortem SARS-CoV-2 RNA from 35 complete COVID-19 autopsies was correlated with the time interval between the first diagnosis of COVID-19 and death and with its relationship to morphologic findings. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA can be evident up to 40 days after the first diagnosis and can persist to 94 hours after death. Postmortem SARS-CoV-2 RNA was mostly positive in lungs (70%) and trachea (69%), but all investigated organs were positive with variable frequency. Late-stage tissue damage was evident up to 65 days after initial diagnosis in several organs. Positivity for SARS-CoV-2 RNA in pulmonary swabs correlated with diffuse alveolar damage ( Our data provide evidence not only of long-term postmortem persisting SARS-CoV-2 RNA but also of tissue damage several weeks after the first diagnosis of SARS-CoV-2 infection. Additional conditions, such as concomitant bacterial pulmonary superinfection, lung aspergillosis, thromboembolic phenomena, and hemorrhages can further worsen tissue damage.

Sections du résumé

BACKGROUND BACKGROUND
Long-term sequelae of coronavirus disease 2019 (COVID-19), including the interaction between persisting viral-RNA and specific tissue involvement, pose a challenging issue. In this study, we addressed the chronological correlation (after first clinical diagnosis and postmortem) between severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA and organ involvement.
METHODS METHODS
The presence of postmortem SARS-CoV-2 RNA from 35 complete COVID-19 autopsies was correlated with the time interval between the first diagnosis of COVID-19 and death and with its relationship to morphologic findings.
RESULTS RESULTS
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA can be evident up to 40 days after the first diagnosis and can persist to 94 hours after death. Postmortem SARS-CoV-2 RNA was mostly positive in lungs (70%) and trachea (69%), but all investigated organs were positive with variable frequency. Late-stage tissue damage was evident up to 65 days after initial diagnosis in several organs. Positivity for SARS-CoV-2 RNA in pulmonary swabs correlated with diffuse alveolar damage (
CONCLUSIONS CONCLUSIONS
Our data provide evidence not only of long-term postmortem persisting SARS-CoV-2 RNA but also of tissue damage several weeks after the first diagnosis of SARS-CoV-2 infection. Additional conditions, such as concomitant bacterial pulmonary superinfection, lung aspergillosis, thromboembolic phenomena, and hemorrhages can further worsen tissue damage.

Identifiants

pubmed: 35223894
doi: 10.3389/fmed.2022.778489
pmc: PMC8865372
doi:

Types de publication

Journal Article

Langues

eng

Pagination

778489

Informations de copyright

Copyright © 2022 Maccio, Zinkernagel, Schuepbach, Probst-Mueller, Frontzek, Brugger, Hofmaenner, Moch and Varga.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
Eur J Radiol. 2020 Dec;133:109393
pubmed: 33161199
Ann Clin Transl Neurol. 2020 Nov;7(11):2221-2230
pubmed: 33016619
Int J Infect Dis. 2021 Apr;105:374-376
pubmed: 33684560
Intensive Care Med. 2020 Jun;46(6):1089-1098
pubmed: 32367170
Clin Microbiol Infect. 2021 Mar;27(3):469.e9-469.e15
pubmed: 33068757
Am J Pathol. 2021 Aug;191(8):1374-1384
pubmed: 34033751
Radiology. 2020 Nov;297(2):E242-E251
pubmed: 32544034
JAMA. 2020 May 12;323(18):1775-1776
pubmed: 32203977
Forensic Sci Int. 2021 Feb;319:110653
pubmed: 33360242
Lancet. 2020 Mar 28;395(10229):1033-1034
pubmed: 32192578
Nat Med. 2021 Apr;27(4):601-615
pubmed: 33753937
JAMA. 2020 Apr 7;323(13):1239-1242
pubmed: 32091533
Cell Mol Immunol. 2021 May;18(5):1305-1307
pubmed: 33742186
Trends Immunol. 2020 Dec;41(12):1083-1099
pubmed: 33153908
Cells. 2021 Mar 10;10(3):
pubmed: 33801959
Stroke. 2017 Apr;48(4):1085-1087
pubmed: 28235962
Mod Pathol. 2021 Sep;34(9):1614-1633
pubmed: 34031537
JAMA. 2020 Aug 25;324(8):782-793
pubmed: 32648899
J Occup Environ Med. 2021 Mar 1;63(3):e159-e162
pubmed: 33405498
BMJ. 2020 Aug 11;370:m3026
pubmed: 32784198
Clin Infect Dis. 2021 Mar 1;72(5):905-906
pubmed: 32544219
Swiss Med Wkly. 2021 Aug 10;151:w20569
pubmed: 34375985
J Thromb Haemost. 2020 Sep;18(9):2110-2117
pubmed: 32608159
JAMA. 2020 Mar 17;323(11):1061-1069
pubmed: 32031570
Clin Infect Dis. 2021 Dec 6;73(11):e3606-e3614
pubmed: 32719848
Int J Environ Res Public Health. 2021 Mar 05;18(5):
pubmed: 33807869
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Front Immunol. 2020 Jun 16;11:1446
pubmed: 32612617
Brain Pathol. 2020 Nov;30(6):1012-1016
pubmed: 32762083
J Immunol. 2020 Sep 15;205(6):1488-1495
pubmed: 32699160
Elife. 2021 Mar 30;10:
pubmed: 33781385
Cell. 2020 Dec 10;183(6):1735
pubmed: 33306958
Lancet. 2021 Jan 16;397(10270):220-232
pubmed: 33428867
J Infect. 2020 Aug;81(2):266-275
pubmed: 32473235
PLoS One. 2020 Jun 23;15(6):e0234765
pubmed: 32574165
Neuropathol Appl Neurobiol. 2021 Apr;47(3):454-459
pubmed: 33249605
J Med Virol. 2021 Jan;93(1):250-256
pubmed: 32592501
Blood Rev. 2021 Jan;45:100707
pubmed: 32425294
J Clin Pathol. 2021 Nov;74(11):752
pubmed: 33184063
J Clin Med. 2020 May 14;9(5):
pubmed: 32422983
AJNR Am J Neuroradiol. 2020 Nov;41(11):2001-2008
pubmed: 32819899
Diagn Histopathol (Oxf). 2021 Mar;27(3):103-107
pubmed: 33312230
Int J Infect Dis. 2020 Dec;101:138-148
pubmed: 33007452
Virchows Arch. 2021 Feb;478(2):343-353
pubmed: 32815036
Arch Pathol Lab Med. 2020 Nov 1;144(11):1298-1302
pubmed: 32589448
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Clin Infect Dis. 2021 Jun 1;72(11):e921
pubmed: 32986798
Clin Infect Dis. 2020 Dec 3;71(9):2459-2468
pubmed: 32358954
Signal Transduct Target Ther. 2020 Dec 4;5(1):283
pubmed: 33277466
J Clin Microbiol. 2020 Jul 23;58(8):
pubmed: 32404482
Am J Surg Pathol. 2021 May 1;45(5):587-603
pubmed: 33481385
Ocul Surf. 2021 Jan;19:322-329
pubmed: 33176215
Infect Control Hosp Epidemiol. 2021 Jan;42(1):84-88
pubmed: 32703320
Microorganisms. 2021 Apr 10;9(4):
pubmed: 33920259
Brain Behav Immun. 2020 Oct;89:543-554
pubmed: 32682993
Cell. 2020 Apr 16;181(2):271-280.e8
pubmed: 32142651
Pathol Res Pract. 2021 Jan;217:153305
pubmed: 33285423
Cell. 2021 Jan 7;184(1):149-168.e17
pubmed: 33278357
J Infect Dis. 2021 Aug 2;224(3):389-394
pubmed: 33999152
Radiology. 2020 Dec;297(3):E313-E323
pubmed: 32677875
Ann Intern Med. 2021 May;174(5):655-662
pubmed: 33481642
Cell Rep Med. 2021 Apr 20;2(4):100229
pubmed: 33748789
Aging Clin Exp Res. 2021 Jan;33(1):193-199
pubmed: 33345291

Auteurs

Umberto Maccio (U)

Department of Pathology and Molecular Pathology, University Hospital of Zürich, University of Zurich, Zurich, Switzerland.

Annelies S Zinkernagel (AS)

Department of Infectious Diseases and Hospital Epidemiology, University Hospital of Zürich, University of Zurich, Zurich, Switzerland.

Reto Schuepbach (R)

Institute of Intensive Care, University Hospital Zurich, University Hospital of Zürich, Zurich, Switzerland.

Elsbeth Probst-Mueller (E)

Department of Immunology, University Hospital of Zürich, Zurich, Switzerland.

Karl Frontzek (K)

Institute of Neuropathology, University Hospital Zurich, Zurich, Switzerland.

Silvio D Brugger (SD)

Department of Infectious Diseases and Hospital Epidemiology, University Hospital of Zürich, University of Zurich, Zurich, Switzerland.

Daniel Andrea Hofmaenner (DA)

Institute of Intensive Care, University Hospital Zurich, University Hospital of Zürich, Zurich, Switzerland.

Holger Moch (H)

Department of Pathology and Molecular Pathology, University Hospital of Zürich, University of Zurich, Zurich, Switzerland.

Zsuzsanna Varga (Z)

Department of Pathology and Molecular Pathology, University Hospital of Zürich, University of Zurich, Zurich, Switzerland.

Classifications MeSH